Why This Brief Exists

Preeclampsia — the hypertensive disorder of pregnancy characterized by new-onset hypertension and proteinuria or end-organ dysfunction after 20 weeks gestation — affects roughly 2–8% of pregnancies worldwide and is a leading cause of maternal and perinatal morbidity and mortality. Despite decades of research, prediction and prevention remain limited. Aspirin prophylaxis helps for high-risk patients, but the underlying etiology is increasingly understood as a disorder of exaggerated maternal inflammatory response to defective placentation — and that inflammatory response is where the oral-systemic connection enters.

This brief consolidates the periodontal disease → preeclampsia evidence base for OB-GYNs, reproductive endocrinologists, and maternal-fetal medicine specialists. It is the fifth spoke in the preconception clinician wedge, sitting alongside the biomarkers hub, the oral pathogens clinician brief, the male-partner screening brief, and the maternal periodontitis brief. For the full actionable ordering workflow that ties these spokes together, see the Preconception Saliva Testing Ordering Pathway.

Key Statistics

• 2–8% of pregnancies are affected by preeclampsia worldwide
• ~2× adjusted odds of preeclampsia in women with periodontal disease (meta-analytic estimates range from 1.5× to 3×)
• ~20% of preeclampsia cases may have a contributable inflammatory component from periodontal disease
• P. gingivalis and its gingipain proteases have been detected in placental tissue in preeclampsia cohorts — see the P. gingivalis deep guide

The Biological Mechanism

Preeclampsia is fundamentally a disorder of the maternal inflammatory response to the placenta. The leading etiological model involves defective early trophoblast invasion and inadequate spiral artery remodeling, which leads to a hypoxic placenta that releases anti-angiogenic factors (sFlt-1, soluble endoglin) and inflammatory mediators into the maternal circulation. The maternal endothelium responds with widespread inflammation, oxidative stress, and the clinical syndrome of hypertension and end-organ damage.

Periodontal disease contributes an additional inflammatory load on top of this placental source. Here is the chain:

1. Periodontal pathogens drive chronic systemic inflammation. Porphyromonas gingivalis, Fusobacterium nucleatum, and the red complex bacteria (T. forsythia, T. denticola) induce local periodontal inflammation that releases pro-inflammatory cytokines (IL-6, TNF-α, CRP) and bacterial products (lipopolysaccharide, gingipains) into the systemic circulation.
2. Bacterial products reach the placenta. P. gingivalis and its gingipain proteases have been detected in placental tissue and amniotic fluid in preeclampsia and adverse pregnancy outcome cohorts, suggesting hematogenous seeding of the maternal-fetal interface.
3. The inflammatory load amplifies the placental inflammatory response. In a patient already primed for an exaggerated inflammatory response (the preeclampsia phenotype), an additional inflammatory input from a treatable local source — the mouth — may push the maternal endothelium past the threshold into clinical disease.
4. The result is earlier or more severe preeclampsia. The added inflammatory burden does not cause preeclampsia in isolation — the disorder requires the placental component — but it may lower the threshold, accelerate onset, or worsen severity.

This is the same “two-hit” inflammatory model described in the maternal periodontitis brief for preterm birth and low birth weight: the placenta provides the first hit (defective placentation), and the oral pathogen load provides the second (systemic inflammation). Preeclampsia and adverse birth outcomes share this mechanistic overlap, which is why the periodontal intervention evidence base spans both outcomes.

What the Evidence Shows

The evidence linking periodontal disease to preeclampsia is observational and mechanistic, not interventional — there are no large RCTs showing that treating periodontal disease prevents preeclampsia. What the evidence does show:

Observational Association

Multiple systematic reviews and meta-analyses report an association between maternal periodontal disease and preeclampsia, with adjusted odds ratios ranging from approximately 1.5 to 3.0 depending on the definition of periodontal disease used and the population studied. The association persists after adjustment for known confounders (BMI, age, smoking, socioeconomic status), though residual confounding is inherent to observational designs.

Placental Pathogen Detection

Studies of placental tissue from preeclampsia and adverse pregnancy outcome cohorts have detected oral bacterial DNA — including P. gingivalis and F. nucleatum — at higher rates than in uncomplicated pregnancies. This supports the hematogenous-seeding mechanism, though detection does not establish causation.

Inflammatory Markers

Women with periodontal disease show elevated systemic inflammatory markers (CRP, IL-6) during pregnancy, and women with preeclampsia show elevated inflammatory markers — the overlap is the mechanistic bridge. Periodontal treatment during pregnancy has been shown to reduce systemic inflammatory markers in some studies, though the effect on preeclampsia incidence specifically is unproven.

Intervention Evidence (Limited)

Studies of periodontal treatment during pregnancy have produced mixed results for adverse pregnancy outcomes broadly. The evidence for preeclampsia prevention specifically is insufficient to recommend treatment as a preeclampsia-prevention strategy. The stronger case — and the case this brief makes — is for preconception screening and treatment, which addresses the inflammatory load before conception rather than during the vulnerable gestational window.

The Preconception Argument

The preconception window is the optimal intervention window for the same reason it is optimal for preterm birth and maternal periodontitis: treatment completed before conception removes the inflammatory burden from the gestational period entirely. This is the core of the ordering pathway argument.

For a patient with preeclampsia risk factors — prior preeclampsia, chronic hypertension, autoimmune disease, advanced maternal age, obesity, or a family history — the preconception visit is the point at which an unaddressed periodontal pathogen load becomes a modifiable, treatable contributor to an otherwise hard-to-prevent condition. The read an OB-GYN would otherwise not have at the preconception visit is whether the patient is carrying a quantified, treatable inflammatory burden in her mouth.

Who to Screen

Screen for periodontal pathogen load at the preconception visit in patients with any of the following:

• Prior preeclampsia — especially early-onset or severe
• Chronic hypertension or gestational hypertension in a prior pregnancy
• Known periodontal diagnosis or visible gum inflammation at the preconception visit
• History of recurrent pregnancy loss or adverse pregnancy outcomes (see the maternal periodontitis brief)
• Family history of preeclampsia
• Elevated baseline CRP on general lab work
• Autoimmune condition with inflammatory overlap (lupus, antiphospholipid syndrome)
• Obesity or metabolic syndrome — elevated inflammatory baseline

For the full screening protocol — panel selection, threshold-based interpretation, treatment, and re-testing — follow the Preconception Saliva Testing Ordering Pathway.

The Clinical Workflow

At the Preconception Visit

1. Assess preeclampsia risk using standard criteria (prior history, BMI, blood pressure, autoimmune status, family history).
2. Screen for periodontal disease — clinical exam for pocket depths and bleeding on probing, plus a clinical-grade salivary pathogen panel for high-risk patients.
3. Refer for periodontal therapy if pathogen load is above treatment threshold or clinical exam shows active disease. Complete treatment preconceptionally.
4. Re-test 4–6 weeks post-therapy to confirm pathogen reduction to below treatment threshold.
5. Clear for conception once pathogen load is controlled and the patient is on aspirin prophylaxis per standard high-risk protocols.

During Pregnancy

Periodontal maintenance during pregnancy is safe and recommended for patients with a history of periodontal disease. The standard trimester-by-trimester dental care guidance applies — see the maternal periodontitis brief for the full gestational management plan. Avoid starting new invasive periodontal therapy in the first trimester; maintenance cleanings in the second trimester are the standard window.

Couples' Screening

Periodontal pathogens are transmissible between intimate partners, and an untreated partner can re-expose a treated patient. For patients on the preconception pathway, screen both partners concurrently. See the Male-Partner Salivary Testing brief for the couples' protocol.

What This Brief Does Not Claim

• Periodontal disease does not cause preeclampsia in isolation. The disorder requires the placental component. The oral-systemic contribution is an inflammatory amplifier, not a root cause.
• Treating periodontal disease has not been proven to prevent preeclampsia. The case is mechanistic and observational, and the intervention is preconception because the gestational window is too late to fully address the inflammatory load.
• Salivary pathogen testing is not a preeclampsia screening test. It is a read on one modifiable inflammatory contributor, used alongside — not in place of — standard preeclampsia risk assessment.

The honest framing for patients and colleagues: we are identifying and removing a treatable inflammatory burden before conception, on the reasoned premise that reducing the total inflammatory load a pregnant patient carries into the gestational window is a sensible precaution in a condition where prevention options are otherwise limited.

Further Reading

• Saliva & Preconception Fertility Hub — the consumer-facing entry point
• Oral Pathogens & Preconception Fertility — Clinician Brief — the citation-ready pathogens evidence
• Male-Partner Salivary Testing — Clinician Brief — the couples' screening protocol
• Maternal Periodontitis & Adverse Pregnancy Outcomes — Clinician Brief — the shared two-hit inflammatory model
• Preconception Saliva Testing Ordering Pathway — the actionable ordering workflow
• Porphyromonas gingivalis — Deep Guide — the keystone pathogen profile
• Fusobacterium nucleatum — Guide — the bridging pathogen profile
• Test Comparison Guide — panel selection
• Action Protocols — treatment workflows

---

This article is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider.

---

Continue the path:

← For Clinicians — The Preconception Oral-Systemic Evidence Path

← For Patients — Your Mouth & Your Fertility Journey